Claudine Isaacs, SABCS 2022: Cemiplimab plus REGN3767 in HER2-negative breast cancer: The I-SPY2 trial
The I-SPY2 trial (NCT01042379) is a multicentre, phase 2 trial where patients with HER2-negative breast cancer were randomized to receive neoadjuvant cemiplimab plus REGN3767 and paclitaxel or weekly paclitaxel for 12 cycles. In this touchONCOLOGY interview, we speak with Prof. Claudine Isaacs (Georgetown University, Washington, DC, USA) who gives an overview of the I-SPY2 study with the rationale for the use of cemiplimab plus REGN3767 as well as discussing the aims, design and findings of the study.
The abstract entitled ‘Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL’ was presented at San Antonio Breast Cancer Symposium (SABCS), 06–10, December, 2022.
- Could you give us a brief overview of the I-SPY2 study? (0:20)
- What is the rationale for the use of cemiplimab and fianlimib in women with breast cancer? (1:11)
- What were the aims, design and eligibility criteria of this I-SPY 2 substudy? (3:27)
- What were the efficacy and safety findings of the study? (4:28)
- Which women are most likely to benefit from this regimen? (9:17)
Disclosures: Claudine Isaacs is a consultant for Genentech, PUMA, Seattle Genetics, AstraZeneca, Novartis, Pfizer, ESAI, Sanofi, ION and Gilead and discloses grant/research support from Tesaro/GSK, Seattle Genetics, Pfizer, AstraZeneca, Bristol Myers Squibb, Genentech and Novartis.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Shanice Allen
Filmed as a highlight of SABCS 2022
Access more content on Breast Cancer
Share this Video
Related Videos In Breast Cancer
Sara Hurvitz, SABCS 2022: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2+ metastatic breast cancer: DESTINY-Breast03
Trastuzumab deruxtecan (T-DXd) is approved in the United States and European Union for use in patients with HER2+ unresectable/metastatic breast cancer. Approval was based on the randomized, multicenter, open-label, phase III DESTINY-Breast03 (NCT03529110) trial. In this interview we discuss with Dr Sara Hurvitz (David Geffen School of Medicine, UCLA Los Angeles, CA, USA) updated data […]
Erika Hamilton, SABCS 2022: Trastuzumab deruxtecan and pertuzumab in HER2+ metastatic breast cancer
Preclinical findings have suggested that when used in combination with anticancer treatments, trastuzumab deruxtecan (T-Dxd) could improve treatment efficacy in HER2+ metastatic breast cancer (mBC). In this interview we discuss with Dr Erika Hamilton (Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN) preliminary data from the dose expansion phase of the DESTINY-Breast07 (DB-07) (NCT04538742) trial. […]
Sudeep Gupta, SABCS 2022: Addition of platinum to neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial
The impact of adding platinum on long-term outcomes in triple-negative breast cancer (TNBC) has not been definitively established. The controlled, single-centre, phase III study conducted by Tata Memorial Hospital in Mumbai, India evaluated the efficacy and toxicity of adding platinum to standard neoadjuvant chemotherapy in patients with triple-negative breast cancer. In this touchONCOLOGY interview, we speak […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!